ClinicalTrials.gg
CompletedNCT02443883Updated Jun 29, 2020Results posted

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

A Phase 2 interventional study of Ramucirumab in Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 45 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-29.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing ramucirumab in Stomach Neoplasms — 3 open to participants now, 4 under way, none of them phase 3. Ramucirumab · Stomach Neoplasms.

Enrollment
7th of 20
164 · median 59
Started
2015
with 1 other
Phase 2
10 of 20
1 open now
Registered
5th of 20
by date
Lead sponsor
6 of 20
Eli Lilly and Company

Among the 20 studies testing ramucirumab in Stomach Neoplasms, this one is the 7th largest by enrollment, is one of 2 that started in 2015, is one of 10 in phase 2, and was the 5th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

3 of the 20 studies testing ramucirumab in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ramucirumab

Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing ramucirumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study was to evaluate the safety and pharmacokinetics of administering various dose regimens of ramucirumab in participants with advanced gastric cancer whose disease has progressed during or following prior chemotherapy.

03

Conditions studied

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma

Browse trials for

Keywords

  • stomach cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a histopathologically or confirmed diagnosis of gastric or gastroesophageal junction (GEJ).
  • The participant has documented disease progression during or within 4 months after the last dose of chemotherapy for disease, or during or within 6 months after the last dose of or adjuvant therapy.
  • The participant received combination chemotherapy prior to disease progression.

    • Prior chemotherapy regimens must include a platinum and/or a fluoropyrimidine component and must not include a taxane or antiangiogenic agent.
  • The participant has metastatic disease or locally advanced disease that is measurable or nonmeasurable, but is evaluable disease by radiological imaging per , Version 1.1 (RECIST 1.1).
  • Patients are eligible if they are considered not appropriate, for whatever reason, for treatment with ramucirumab in combination with paclitaxel.
  • The participant has an (ECOG) performance status of 0 or 1.
  • The participant has adequate organ function, including:

    • Total 1.5 × the upper limit of institutional normal () and (ALT) and aspartate aminotransferase (AST) 3 × ULN. If the liver has tumor involvement, AST and ALT \<5 × ULN are acceptable.
    • Serum creatinine 1.5 × ULN or calculated (per the Cockcroft-Gault formula or equivalent and/or 24-hour urine collection) 60 milliliters/minute (mL/min).
    • Urinary protein is \<2+ on dipstick or routine urinalysis.
    • 1.5 × 10\^9/Liter (L), 100 × 10\^9/L, and 9 g/deciliter (dL) (5.58 millimoles/Liter).
    • 1.5 × ULN or prothrombin time 5 seconds above ULN.
    • Partial thromboplastin time 5 seconds above ULN.
  • The participant has an estimated of 12 weeks in the judgment of the investigator.
  • The participant, if female and of , must have a negative serum or urine pregnancy test within 7 days prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • The participant has squamous cell or undifferentiated gastric cancer.
  • The participant is receiving chronic therapy with any of the following within 7 days prior to randomization:

    • Nonsteroidal anti-inflammatory agents (NSAIDs; such as indomethacin, ibuprofen, naproxen, or similar agents), or
    • Other anti- agents (such as clopidogrel, ticlopidine, dipyridamole, or anagrelide). Aspirin use at doses up to 325 milligrams (mg)/day is permitted.
  • The participant received radiotherapy within 14 days prior to randomization.
  • The participant received >1 for the treatment of locally advanced and unresectable or gastric or GEJ (Siewert Types I-III) adenocarcinoma.
  • The participant received previous treatment with agents targeting the vascular endothelial growth factor (VEGF)/VEGF receptor 2 signaling pathway.
  • The participant has documented , , or uncontrolled spinal cord compression.
  • The participant experienced any arterial thromboembolic event, including myocardial infarction, unstable angina, cerebrovascular accident, or , within 6 months prior to randomization.
  • The participant has symptomatic congestive heart failure ( II-IV) or symptomatic or poorly controlled cardiac arrhythmia.
  • The participant has uncontrolled hypertension, as defined in (CTCAE) Version 4.0, prior to initiating study treatment, despite antihypertensive intervention.
  • The participant underwent major surgery within 28 days prior to randomization or central venous access device placement within 7 days prior to randomization.
  • The participant has a history of gastrointestinal perforation or fistula within 6 months prior to randomization.
  • The participant has any condition (for example, psychological, geographical, or medical) that does not permit compliance with the study and follow-up procedures or suggests that the participant is, in the investigator's opinion, not an appropriate candidate for the study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    Ramucirumab Regimen 1

    Standard dose of 8 milligram per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.

    Drug: Ramucirumab

  • Experimental
    Ramucirumab Regimen 2

    Experimental dose of 12 mg/kg ramucirumab given IV on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.

    Drug: Ramucirumab

  • Experimental
    Ramucirumab Regimen 3

    Experimental dose of 6 mg/kg ramucirumab given IV on day 1, 8, 15 and 22 of each cycle (28-day cycle) until discontinuation criteria are met.

    Drug: Ramucirumab

  • Experimental
    Ramucirumab Regimen 4

    Experimental dose of 8 mg/kg ramucirumab given IV on day 1 and day 8 of each cycle (21-day cycle) until discontinuation criteria are met.

    Drug: Ramucirumab

Interventions

  • Administered IV

    Also known as: LY3009806, IMC-1121B

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab

    The Cmin is the minimum observed serum concentration of ramucirumab.

    Time frame: Day 29, 43, 71 and 85: predose

Secondary outcomes

  1. Immunogenicity: Number of Participants With Anti-Ramucirumab Antibodies

    Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.

    Time frame: Predose Cycle 1 Through Short Term Follow Up (Up to 5 Months)

  2. Rate of Progression Free Survival (PFS) at the First 6-Week Tumor Assessment

    PFS defined as the time from first day of therapy to first evidence of disease progression per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) or death from any cause up to the first 6-week tumor assessment. Progressive Disease (PD) is at least 20% increase in sum of diameters of target lesions,taking as reference smallest sum on study and absolute increase of at least 5 mm.Appearance of 1 or more new lesions was also considered progression. Nontarget PD is unequivocal progression of existing nontarget lesions.Appearance of 1 or more new nontarget lesions was also considered PD.Participants with no baseline disease assessment: PFS time was censored at the randomization date,regardless of whether or not objectively determined disease progression or death has been observed.

    Time frame: Baseline until the first 6-week tumor assessment

07

Results

Posted Mar 13, 2018

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab Regimen 1Ramucirumab Regimen 2Ramucirumab Regimen 3Ramucirumab Regimen 4
Started40424141
Received at least one dose of study drug38424140
Completed34384036
Not completed6415
Withdrew: Adverse event0100
Withdrew: Lost to follow-up3210
Withdrew: Physician decision1103
Withdrew: Withdrawal by subject1002
Withdrew: Randomized, but never treated1000

Outcome measures

PrimaryPharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab

The Cmin is the minimum observed serum concentration of ramucirumab.

Time frame:
Day 29, 43, 71 and 85: predose
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
microgram per milliliter (µg/mL)Ramucirumab Regimen 1Ramucirumab Regimen 2Ramucirumab Regimen 3Ramucirumab Regimen 4
Day 2932.9 ± 5159.5 ± 6069.3 ± 4571.6 ± 37
Day 4347.6 ± 3671.0 ± 5883.0 ± 5757.4 ± 44
Day 7160.4 ± 3465.0 ± 60122 ± 6597.1 ± 46
Day 8564.3 ± 4079.4 ± 46125 ± 5681.6 ± 50
SecondaryImmunogenicity: Number of Participants With Anti-Ramucirumab Antibodies

Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.

Time frame:
Predose Cycle 1 Through Short Term Follow Up (Up to 5 Months)
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants With Anti-Ramucirumab Antibodies
ParticipantsRamucirumab Regimen 1Ramucirumab Regimen 2Ramucirumab Regimen 3Ramucirumab Regimen 4
Immunogenicity: Number of Participants With Anti-Ramucirumab Antibodies0000
SecondaryRate of Progression Free Survival (PFS) at the First 6-Week Tumor Assessment

PFS defined as the time from first day of therapy to first evidence of disease progression per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) or death from any cause up to the first 6-week tumor assessment. Progressive Disease (PD) is at least 20% increase in sum of diameters of target lesions,taking as reference smallest sum on study and absolute increase of at least 5 mm.Appearance of 1 or more new lesions was also considered progression. Nontarget PD is unequivocal progression of existing nontarget lesions.Appearance of 1 or more new nontarget lesions was also considered PD.Participants with no baseline disease assessment: PFS time was censored at the randomization date,regardless of whether or not objectively determined disease progression or death has been observed.

Time frame:
Baseline until the first 6-week tumor assessment
Reported as:
Number · Percentage of participants
Rate of Progression Free Survival (PFS) at the First 6-Week Tumor Assessment
Percentage of participantsRamucirumab Regimen 1Ramucirumab Regimen 2Ramucirumab Regimen 3Ramucirumab Regimen 4
Rate of Progression Free Survival (PFS) at the First 6-Week Tumor Assessment43.9 (27.3 to 59.3)61.9 (44.9 to 75.0)53.0 (36.2 to 67.3)51.2 (34.2 to 65.9)

Adverse events

Collected over Up To 3 Years and 3 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab Regimen 1—10/38 (26.3%)30/38 (78.9%)
Ramucirumab Regimen 2—11/42 (26.2%)31/42 (73.8%)
Ramucirumab Regimen 3—10/41 (24.4%)36/41 (87.8%)
Ramucirumab Regimen 4—18/40 (45%)31/40 (77.5%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventRamucirumab Regimen 1Ramucirumab Regimen 2Ramucirumab Regimen 3Ramucirumab Regimen 4
VomitingGastrointestinal disorders1/381/420/414/40
Gastric haemorrhageGastrointestinal disorders0/380/423/410/40
Non-cardiac chest painGeneral disorders2/380/420/410/40
PyrexiaGeneral disorders2/380/420/410/40
Abdominal painGastrointestinal disorders1/382/420/412/40
DysphagiaGastrointestinal disorders0/381/421/412/40
PneumoniaInfections and infestations0/382/420/411/40
Cardiac arrestCardiac disorders1/381/420/410/40
Duodenal ulcer haemorrhageGastrointestinal disorders1/380/420/410/40
Gastric perforationGastrointestinal disorders1/380/420/410/40
Most frequent other events
Showing 10 of 38
Most frequent other events
EventRamucirumab Regimen 1Ramucirumab Regimen 2Ramucirumab Regimen 3Ramucirumab Regimen 4
FatigueGeneral disorders10/3812/426/419/40
Decreased appetiteMetabolism and nutrition disorders8/389/4211/417/40
Abdominal painGastrointestinal disorders6/3810/427/414/40
DiarrhoeaGastrointestinal disorders3/389/424/415/40
VomitingGastrointestinal disorders6/386/428/417/40
ConstipationGastrointestinal disorders2/385/427/417/40
NauseaGastrointestinal disorders6/384/424/417/40
HypertensionVascular disorders6/382/427/416/40
Aspartate aminotransferase increasedInvestigations6/385/423/411/40
EpistaxisRespiratory, thoracic and mediastinal disorders1/382/426/412/40

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Ramucirumab Regimen 1Ramucirumab Regimen 2Ramucirumab Regimen 3Ramucirumab Regimen 4Total
Mean58.5 ± 14.058.7 ± 10.460.5 ± 12.356.2 ± 12.958.5 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab Regimen 1Ramucirumab Regimen 2Ramucirumab Regimen 3Ramucirumab Regimen 4Total
Female11106936
Male29323532128
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ramucirumab Regimen 1Ramucirumab Regimen 2Ramucirumab Regimen 3Ramucirumab Regimen 4Total
Hispanic or Latino636722
Not Hispanic or Latino32373332134
Unknown or Not Reported22228
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ramucirumab Regimen 1Ramucirumab Regimen 2Ramucirumab Regimen 3Ramucirumab Regimen 4Total
American Indian or Alaska Native00000
Asian10012
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White32353533135
More than one race675624
Unknown or Not Reported10113
Region of Enrollment
Region of Enrollment(Participants)Ramucirumab Regimen 1Ramucirumab Regimen 2Ramucirumab Regimen 3Ramucirumab Regimen 4Total
New Zealand21137
Argentina512614
Romania4610727
Turkey342211
Hungary03317
United States23218
Poland667524
United Kingdom7108631
Slovakia31217
Australia12058
France11215
Russia642315
08

Study locations

45 sites
  • Arizona Clinical Research Center
    Tucson, Arizona 85715, United States
  • USC Norris Cancer Hospital
    Los Angeles, California 90033, United States
  • Carolinas Medical Center
    Charlotte, North Carolina 28204, United States
  • Oklahoma Cancer Specialists & Research Institute, LLC
    Tulsa, Oklahoma 74146, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, 1025, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rosario, 2000, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Miguel de Tucumán, T4000IAK, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Viedma, 8500, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Adelaide, 5000, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kingswood, 2747, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Melbourne, 3144, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nedlands, 6009, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brest, 29609, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Creteil, 94010, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dijon, 21079, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon, 69437, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75012, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75013, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Budapest, 1125, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szolnok, 5000, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Auckland, 1023, New Zealand
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Christchurch, 8011, New Zealand
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdansk, 80-219, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lodz, 90-242, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poznan, 61-485, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warszawa, 04-125, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Baia Mare, 430031, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Cluj-Napoca, 400058, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Craiova, 200347, Romania
  • Arkhangelsk Regional Clinical Oncology Dispensary
    Arkhangelsk, 163045, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kursk, 305035, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Moscow, 115478, Russian Federation
  • Leningrad regional clinical hospital
    St. Petersburg, 194291, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Bratislava, 833 10, Slovakia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Kosice, 041-90, Slovakia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Edirne, 22030, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fatih, 34093, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pendik, 34668, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yüregir, 1250, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cardiff, CF14 2TL, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Exeter, EX2 5DW, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leeds, LS9 7TF, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manchester, M20 4BX, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wolverhampton, WV10 0QP, United Kingdom
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and european union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Nov 2016, 16 months.

Results were first posted in Mar 2018, 1 year 3 months after primary completion.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 16 months is below that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2015
First posted
May 14, 2015
StartActual
Jul 7, 2015
Primary completionActual
Nov 18, 2016
CompletionActual
Jun 5, 2019
Results first posted
Mar 13, 2018
Last update
Jun 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02443883
Responsible party
Sponsor
First posted
May 14, 2015
Start date
Jul 7, 2015
Primary completion
Nov 18, 2016
Completion
Jun 5, 2019
Results posted
Mar 13, 2018
Last update
Jun 29, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion